Bayer Highlights Hemophilia Strategy As Newer Drugs Carry Pharma Unit In Q2
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will prioritize potential Kogenate successor Kovaltry for hemophilia A, and delay filing of BAY 94-9027.